Device Trial Radar · NCT02677974
On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
510
Actual
Start
Nov 10, 2015
Primary completion
Apr 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- On-X Life Technologies, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- North American Science Associates Inc.
- First posted
- Feb 9, 2016
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the proposed study is to assess the occurrence of bleeding, valve-related thromboembolism and valve thrombosis with the On-X Aortic Prosthetic Heart Valve when targeted at an International Normalized Ratio (INR) level of 1.8 (1.5-2.0 range) during a 5-year follow-up period. The objective will be to compare adverse event rates for patients in subgroups as listed below targeted at 1.8 (range 1.5 to 2.0) per On-X instructions for use to rates from the previous IDE trial (G050208).
Conditions
- Thrombotic and Bleeding Events
Interventions
On-X Aortic Heart Valve replacementDevice
Aortic valve replacement with low dose warfarin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Thrombotic eventsTime frame: 5 years
- Major bleedsTime frame: 5 years
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
Arizona Cardiothoracic & Neurology
Tucson, Arizona
Hartford Hospital
Hartford, Connecticut
Franciscan St. Francis
Indianapolis, Indiana
20 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.